The assays measure phosphorylated tau 181 and apolipoprotein 4 to rule out whether a patient has Alzheimer's disease.

The firm said that investors provided better-than-expected backing as the company anticipates growing use of its digital pathology platform in 2025.

The aggregate repurchase authorization program now totals $200 million, which the firm will fund with cash and cash equivalents.

The solution enables the use of BD's Synapsis informatics with BD Phoenix M50 automated microbiology and rapid identification and AST on the BDXpert system.

The firm recently announced agreements with Labcorp and Quest Diagnostics to provide its devices for self-collection of vaginal swab specimens.

While AI-based tools have become widely used for documentation and clerical tasks, developers and healthcare experts see a greater future role in clinical care.

IBL will develop biomarker panels for use with Grifols' random-access, single-molecule counting platform, and the firms will collaborate on testing workflows.

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

The ruling makes clear that the FDA lacks the legal authority to regulate LDTs, and observers suggest it could also call into question its authority in other areas.